

Amendment to Share Consolidation Timetable

Sydney, New South Wales, 15 January 2026 – The directors of Invictus Therapeutics Ltd (**Invictus**) (formerly VGI Health Technology Limited (NSX:VTL)) refer to the Company's announcements of 28 November 2025 and 23 December 2025 regarding the timetable for the share consolidation which was approved by Shareholders at the 2025 Annual General Meeting held on 28 November 2025.

Due to unforeseen delays in the administrative process, the Completion Date has been delayed. The Company will send a further update with a new timetable in due course.

This announcement was authorised for release by the Managing Director.

For more information please contact:

Glenn Tong, CEO and Managing Director
Ph: +61 (0) 412 193 350

Catriona Glover, Company Secretary
Tel: +61 (0) 402 328 200

About Invictus Therapeutics Ltd

Invictus Therapeutics Ltd (formerly VGI Health Technology Limited (NSX:VTL)) is an Australian public listed biotechnology company developing and commercialising prescription medicines and novel dietary supplements based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD), Metabolic dysfunction-Associated Steatohepatitis (MASH), pancreatic adenocarcinoma (pancreatic cancer), hyperlipidaemia, hypertension and diabetes. Invictus owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a clinical development program for prescription medicines and a product development program for evidence-based nutraceuticals.